SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Borrow money from friend, debt and loan, incentive or bonus payment, credit or lending concept, businessman hand giving money banknote to friend's hand.
FDA
FDA To Offer Bonus Payments for Speedy Drug Reviewers
FDA Commissioner Marty Makary presented a new idea to staff this week: bonus payments for employees that complete regulatory review processes faster than expected.
February 27, 2026
 · 
1 min read
 · 
Annalee Armstrong
Female hand showing thumbs up gesture on blue background, art collage. Positive hand sign. Fashion collage in the style of Thumbs up magazine. Contemporary art. Modern design.
Approvals
Boehringer Wins Speedy Lung Cancer Approval Under Commissioner’s Priority Program
Hernexeos is the second drug to secure an FDA approval under the agency’s priority voucher scheme, following in the footsteps of USAntibiotics’ Augmentin XR, which was granted the ticket in December 2025.
February 27, 2026
 · 
2 min read
 · 
Tristan Manalac
Finding Talented People. Big Hands with Magnifying Glass Recruiting People. vector
FDA
Prasad Under Probe for Promoting Workplace Toxicity, Staffers Say
Aside from creating a toxic work environment, CBER Director Vinay Prasad has also been accused of berating his staff and retaliating against reviewers who questioned his decisions.
February 27, 2026
 · 
2 min read
 · 
Tristan Manalac
Digital compass. Business strategic explorer, Vision crisis, Mission path, Agency creative, Digital strategy, Market decision, Achievement strategy, Financial stock, Company vision concepts
Policy
FDA Policy Tracker 2026: One-Trial Drug Applications, Guidelines for Personalized Therapies
A year of significant policy change at the FDA brought momentum and scrutiny into the new year. As 2026 gets underway, biopharma companies are responding to sweeping vaccine changes while concerns surface about the politicization of the agency.
February 27, 2026
 · 
7 min read
 · 
BioSpace Editorial Staff
FDA commissioner Marty Makary speaking on a Youtube video, wearing a dark suit and a blue tie
Regulatory
Makary Defends FDA’s Decision-Making Amid Contentious Rare Disease Rejections
Without naming a specific product, Commissioner Marty Makary referred to an investigational therapy, delivered surgically into the brain, that the FDA was “pressured” to approve even after finding no clinical benefit to patients.
February 27, 2026
 · 
2 min read
 · 
Tristan Manalac
IPO Initial Public Offering finance business concept. 3D render vector illustration of Trading on IPO Initial Public Offering, Business Startup and Stock Market Concept. Public offering share launch
IPO tracker
Generate Clocks Largest IPO Since 2024 With $400M Raise
Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year.
February 27, 2026
 · 
5 min read
 · 
Tristan Manalac
The Westin St. Francis in San Francisco, home of the J.P. Morgan Healthcare Conference.
Special edition
Deep Dive: BioSpace Takes On JPM26 in San Francisco
The BioSpace team hit the ground running at the J.P. Morgan Healthcare Conference earlier this month to bring you the news from the streets of San Francisco.
February 27, 2026
 · 
2 min read
 · 
Annalee Armstrong
Businessman facing gap obstacle to achieve his goal. Obstacle and overcome concept vector illustration
Earnings
After Sarepta’s Annus Horribilis, Elevidys Sales Expected To Continue Downward Spiral
After a rocky 2025, Sarepta Therapeutics’ executives admit they have work to do to bring patients back into the fold as sales of Duchenne muscular dystrophy gene therapy Elevidys continue to decline.
February 26, 2026
 · 
5 min read
 · 
Annalee Armstrong
Two men walking on separate winding paths that merge into a single large upward arrow representing business partnership and shared goals, 3d render
FDA
FDA’s One Trial Policy Not a Revolution but a Potentially Risky Evolution
Last week, the FDA made its one pivotal trial policy official, sparking myriad questions from industry leaders, including around specific evidence required for the single study and why it hasn’t been implemented across all therapeutic areas before now.
February 26, 2026
 · 
7 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS